Mike Youle

4.3k total citations
62 papers, 2.6k citations indexed

About

Mike Youle is a scholar working on Infectious Diseases, Virology and Emergency Medicine. According to data from OpenAlex, Mike Youle has authored 62 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Infectious Diseases, 40 papers in Virology and 12 papers in Emergency Medicine. Recurrent topics in Mike Youle's work include HIV Research and Treatment (40 papers), HIV/AIDS Research and Interventions (40 papers) and HIV/AIDS drug development and treatment (39 papers). Mike Youle is often cited by papers focused on HIV Research and Treatment (40 papers), HIV/AIDS Research and Interventions (40 papers) and HIV/AIDS drug development and treatment (39 papers). Mike Youle collaborates with scholars based in United Kingdom, United States and Canada. Mike Youle's co-authors include Margaret Johnson, Caroline Sabin, Clive Loveday, Helen Devereux, Andrew Phillips, Fiona Lampe, Colette Smith, Anton Pozniak, Elna van der Ryst and T.M. Jenkins and has published in prestigious journals such as Nature Medicine, PLoS ONE and Journal of Virology.

In The Last Decade

Mike Youle

60 papers receiving 2.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mike Youle United Kingdom 28 1.9k 1.6k 565 361 288 62 2.6k
William Spreen United States 30 2.4k 1.3× 1.8k 1.1× 693 1.2× 344 1.0× 381 1.3× 80 3.6k
Catherine Godfrey United States 25 1.8k 0.9× 1.3k 0.8× 752 1.3× 651 1.8× 174 0.6× 80 2.8k
Michael F. Para United States 21 1.3k 0.7× 1.0k 0.6× 531 0.9× 411 1.1× 170 0.6× 55 2.0k
Isabelle Pellegrin France 28 1.4k 0.8× 1.5k 0.9× 491 0.9× 378 1.0× 309 1.1× 70 2.1k
Kenneth Rich United States 32 1.9k 1.0× 1.2k 0.7× 869 1.5× 881 2.4× 414 1.4× 80 3.3k
Cynthia A. Kleeberger United States 16 1.0k 0.6× 1.3k 0.8× 423 0.7× 348 1.0× 696 2.4× 19 2.4k
Lı́dia Ruiz Spain 36 2.6k 1.4× 2.4k 1.5× 525 0.9× 535 1.5× 287 1.0× 102 4.4k
Robert Zangerle Austria 29 851 0.5× 698 0.4× 833 1.5× 377 1.0× 268 0.9× 81 2.4k
Lucia Palmisano Italy 24 1.1k 0.6× 930 0.6× 295 0.5× 234 0.6× 154 0.5× 74 1.7k
Sylvie Abel Martinique 25 1.1k 0.6× 794 0.5× 473 0.8× 154 0.4× 220 0.8× 62 2.0k

Countries citing papers authored by Mike Youle

Since Specialization
Citations

This map shows the geographic impact of Mike Youle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mike Youle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mike Youle more than expected).

Fields of papers citing papers by Mike Youle

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mike Youle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mike Youle. The network helps show where Mike Youle may publish in the future.

Co-authorship network of co-authors of Mike Youle

This figure shows the co-authorship network connecting the top 25 collaborators of Mike Youle. A scholar is included among the top collaborators of Mike Youle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mike Youle. Mike Youle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hayes, Aimee R., Kate Smith, Man Liu, et al.. (2021). Treating neuroendocrine neoplasms in the setting of HIV infection. 5(3-4). 143–159.
2.
Dragović, Gordana, et al.. (2016). Choice of first-line antiretroviral therapy regimen and treatment outcomes for HIV in a middle income compared to a high income country: a cohort study. BMC Infectious Diseases. 16(1). 106–106. 9 indexed citations
3.
Katlama, Christine, Sidonie Lambert-Niclot, Lambert Assoumou, et al.. (2015). Treatment intensification followed by interleukin-7 reactivates HIV without reducing total HIV DNA. AIDS. 30(2). 221–230. 54 indexed citations
4.
Beck, Eduard J., Sundhiya Mandalia, Mike Youle, et al.. (2011). Cost-Effectiveness of Early Treatment with First-Line NNRTI-Based HAART Regimens in the UK, 1996-2006. PLoS ONE. 6(5). e20200–e20200. 12 indexed citations
5.
Youle, Mike. (2007). Acetyl-L-Carnitine in HIV-Associated Antiretroviral Toxic Neuropathy. CNS Drugs. 21(Supplement 1). 25–30. 26 indexed citations
6.
Lampe, Fiona, José M. Gatell, Schlomo Staszewski, et al.. (2006). Changes Over Time in Risk of Initial Virological Failure of Combination Antiretroviral Therapy. Archives of Internal Medicine. 166(5). 521–521. 68 indexed citations
7.
Fätkenheuer, Gerd, Anton Pozniak, Margaret Johnson, et al.. (2005). Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nature Medicine. 11(11). 1170–1172. 386 indexed citations
8.
Herzmann, Christian, Margaret Johnson, & Mike Youle. (2005). Long-Term Effect of Acetyl-L-Carnitine for Antiretroviral Toxic Neuropathy. HIV Clinical Trials. 6(6). 344–350. 30 indexed citations
9.
Sabin, Caroline, Colette Smith, Mike Youle, et al.. (2005). Deaths in the era of HAART: contribution of late presentation, treatment exposure, resistance and abnormal laboratory markers. AIDS. 20(1). 67–71. 75 indexed citations
10.
Sabin, Caroline, Teresa Hill, Fiona Lampe, et al.. (2005). Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort study. BMJ. 330(7493). 695–695. 64 indexed citations
11.
Hart, Andrew, Andrew Wilson, Colette Smith, et al.. (2004). Acetyl-l-carnitine. AIDS. 18(11). 1549–1560. 71 indexed citations
12.
Kyriakides, Tassos C., Abdel G. Babiker, Joel Singer, et al.. (2003). An open-label randomized clinical trial of novel therapeutic strategies for HIV-infected patients in whom antiretroviral therapy has failed: rationale and design of the OPTIMA Trial. Controlled Clinical Trials. 24(4). 481–500. 24 indexed citations
13.
Youle, Mike, Mervyn Tyrer, Martin Fisher, et al.. (2002). Two-Year Outcome of a Multidrug Regimen in Patients Who Did Not Respond to a Protease Inhibitor Regimen. JAIDS Journal of Acquired Immune Deficiency Syndromes. 29(1). 58–61. 14 indexed citations
14.
Schrooten, Ward, Robert Colebunders, Mike Youle, et al.. (2001). Sexual dysfunction associated with protease inhibitor containing highly active antiretroviral treatment. AIDS. 15(8). 1019–1023. 90 indexed citations
15.
Devereux, Helen, Clive Loveday, Mike Youle, et al.. (2000). Substantial Correlation between HIV Type 1 Drug-Associated Resistance Mutations in Plasma and Peripheral Blood Mononuclear Cells in Treatment-Experienced Patients. AIDS Research and Human Retroviruses. 16(11). 1025–1030. 37 indexed citations
16.
Youle, Mike, G Jánossy, Clive Loveday, et al.. (2000). Changes in CD4 lymphocyte counts after interruption of therapy in patients with viral failure on protease inhibitor-containing regimens. AIDS. 14(12). 1717–1720. 33 indexed citations
17.
Marshall, Deborah A., Kit N. Simpson, Edward C. Norton, Andrea K. Biddle, & Mike Youle. (2000). MEASURING THE EFFECT OF CLINICAL GUIDELINES ON PATIENT OUTCOMES. International Journal of Technology Assessment in Health Care. 16(4). 1013–1023. 11 indexed citations
18.
Cookson, Sharon, E M Carlin, Mike Youle, et al.. (1997). A Double-Blind Placebo-Controlled Phase II Trial of Thalidomide in Asymptomatic HIV-Positive Patients: Clinical Tolerance and Effect on Activation Markers and Cytokines. AIDS Research and Human Retroviruses. 13(18). 1625–1631. 29 indexed citations
19.
Vandamme, Anne–Mieke, Zeger Debyser, Rudi Pauwels, et al.. (1994). Characterization of HIV-1 Strains Isolated from Patients Treated with TIBO R82913. AIDS Research and Human Retroviruses. 10(1). 39–46. 36 indexed citations
20.
Naylor, Paul H., Marcelo B. Sztein, Scott H. Maurer, et al.. (1991). Preclinical and clinical studies on immunogenicity and safety of the HIV-1 p17-based synthetic peptide AIDS vaccine — HGP-30-KLH. International Journal of Immunopharmacology. 13. 117–127. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by William Spreen Breakdown of academic impact, for papers by Catherine Godfrey Breakdown of academic impact, for papers by Michael F. Para Breakdown of academic impact, for papers by Isabelle Pellegrin Breakdown of academic impact, for papers by Kenneth Rich Breakdown of academic impact, for papers by Cynthia A. Kleeberger Breakdown of academic impact, for papers by Lı́dia Ruiz Breakdown of academic impact, for papers by Robert Zangerle Breakdown of academic impact, for papers by Lucia Palmisano Breakdown of academic impact, for papers by Sylvie Abel
Rankless by CCL
2026